Unum Therapeutics Inc (NASDAQ:UMRX) Q1 2019 Earnings Conference Call - Final Transcript
May 13, 2019 • 08:00 am ET
to develop a BCMA targeted therapy for multiple myeloma, we've made good progress through the early stages of dose escalation in our ongoing ATTCK-17-01 Phase I trial with a first in human targeted antibody. With three required low dose cohorts cleared in 2018, as dose escalation continues into 2019, we're moving into dose levels that may be expected to have pharmacological activity based on preclinical studies.
Our focus on developing therapies to address solid tumors continues to grow. We've now activated multiple clinical sites in the ATTCK-34-01 study, our first ACTR T-cell study targeting HER2-positive advanced cancers. We expect additional sites to come online through the year, as we continue to enroll and treat patients with dose escalation phase of the study. We're also continuing preclinical studies with BOXR1030, our first product candidate to emerge from our BOXR or Bolt-On Chimeric Receptor platform. The BOXR platform was developed to broadly enable engineered T-cell therapies in solid tumors by overcoming immunosuppression in the tumor microenvironment. We look forward to progressing this program towards potential future clinical testing.
I'll now turn it to Mike to discuss updates from our ongoing clinical pipeline.
Thanks, Chuck. We continue to be very excited about our product candidates' potential, as well as the productivity of the ACTR platform that's led to our pipeline depth in both hematologic and solid tumors. Starting with our hematologic programs, we've continued to make progress with our lead product candidate, ACTR707, in combination with rituximab to treat relapsed/refractory non-Hodgkin lymphoma. We presented preliminary results from our ATTCK-20-03 Phase I study at the 2018 ASH Annual Meeting in December, sharing data for patients treated at the first two dose levels. We showed that four patients out of nine treated achieved a complete response without dose limiting toxicities.
We've continued to advance the dose escalation phase of the trial, completing enrollment at Dose Level 3 earlier this year. All patients in this cohort were treated with 55 million ACTR707 dose and no dose limiting toxicities were observed, allowing us to advance to Dose Level 4. We're continuing to enroll and treat patients in this cohort at 18 million ACTR+ T cells. As of last week, no DLTs and no severe adverse events of cytokine release syndrome or neurologic events have been reported in this trial. We've plan to complete dose escalation in the second half of 2019 and based on these data, define a preliminary recommended Phase II dose of ACTR707.
Several different patient populations with non-Hodgkin lymphoma may benefit from the ACTR707, rituximab combination. We look to include such patients in safety expansion cohorts at the preliminary recommended Phase II dose and plan to refinalize to allow us to treat those patients in the study. We anticipate initiating enrollment in the safety expansion phase as early as the second half of this year and continuing into 2020, and we expect to report data from the dose escalation phase of the trial at the end of the year.
In parallel, we're wrapping up